Leonardo Roever Shares a Study on Eligibility Criteria for Endovascular Thrombectomy
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared on LinkedIn:
”Endovascular Thrombectomy for Acute Stroke: Evolving Eligibility Criteria and Adjuvant Therapies
In this review, the authors present recent developments, highlighting how biological targets align with the pathophysiological chronology of primary and secondary injury after an ischemic stroke.
It also discusses why some clinical trials have demonstrated success and others may not, and proposes important considerations for the planning of future trials.
This synthesis aims to inform about the evolving evidence for the treatment of acute ischemic stroke and inspire the planning of clinical trials and next-generation therapies.
See the article.
Follow me for more content on evidence, management, and innovation in healthcare!”
Read the full article here.
Article: Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies
Authors: Martina Glavan, Jia Liu, Gisele Sampaio Silva, Thanh N Nguyen, Jiangbing Zhou, Nenad Sestan et al.

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events